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resistant to the atirretroviral (ARV) drugs available.
METHODS: A Markov model was developed to simulate the
clinical progression of the population analyzed in the clinical
trial with a 48 weeks treatment period. A cost-effectiveness
analysis of ENF in terms of incremental cost per life year gained
(LYG) was obtained. The model was designed over a time
horizon of 10 years with monthly cycles and taking into account
the perspective of the Spanish National Health Service. The
primary clinical outcome was time until death. Efﬁcacy rates and
transition probabilities were obtained from reported clinical and
epidemiological trials. Resource use data was retrieved from
published literature in the Spanish setting and a panel of clinical
opinion leaders. Unit costs were converted to euros and adjusted
for the year 2003. RESULTS: Adding ENF to OT increases
patient’s life expectancy by 1.6 years. Total costs are €117,375
for OT and €159,121 with ENF + OT, mainly due to the fact
that increasing life expectancy for a given cohort of patients,
increases resource use and costs. Incremental cost per life year
gained with ENF is €25,687, which is similar to the value pre-
viously reported when considering results with only 24 weeks of
treatment (€24,780). CONCLUSIONS: ENF used in combina-
tion with an OT regimen increases life expectancy for HIV-1
treated patients who are highly ARV-experienced and delays
onset of new AIDS-deﬁning events, resulting in an economically
efﬁcient treatment option.
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OBJECTIVES: To estimate health care costs in ambulatory
patients living with HIV/AIDS in Spain. To identify signiﬁcative
variables associated to health care costs. METHODS: This is a
retrospective cohort study in which patients were followed up
one year, stratiﬁed by CDC-disease stage (asymptomatic-HIV,
symptomatic-HIV and AIDS). 572 patients agreed to join the
study during an outpatient visit. Data on health care services use
and costs were obtained from clinical records. Direct costs were
divided into hospitalisations, ambulatory care and drug costs.
Quality of life data from patients were obtained through EQ-5D
questionnaire. RESULTS: The mean (SD) annual health care
costs per patient in 2003 were € 8308 (4660). The main contri-
bution came from drugs (82.2% of direct costs), while hospital-
isations only represented a 4.6% of health care costs. We
identiﬁed signiﬁcative associations between health care costs
(dependent variable) and the way of contagious, the stage of
disease, health-related quality of life (HRQOL) and level of
defense in the previous year (independent variable). For instance,
a patient with a low level of defenses in the period t-1 (CD4 cell
< 200, in t-1) would have an incremental cost of 3240–4000
euros in the period t. We repeat the analysis considering phar-
maceutical costs and inpatient costs as dependent variables.
CONCLUSIONS: A high proportion of total direct costs for
people living with HIV/AIDS is due to highly active antiretrovi-
ral therapy (HAART). The current trend in Spain seems to be
shifting resources utilization from hospital admission towards
antiretroviral therapy and outpatients services. We identify sig-
niﬁcative associations between costs, clinical and HRQOL vari-
ables. This information can be useful in the development of
economic evaluation models and for the health care decisors in
the optimal allocation of resources.
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OBJECTIVES: Past studies have indicated that regimen compli-
ance is associated with virological failure which, in turn, impacts
the cost of treating HIV/AIDS. We calculated the per-patient cost
of HIV/AIDS treatment in two African countries based on
recently reported compliance studies and treatment costs.
METHODS: Patient compliance rates from recent studies in two
African countries (South Africa and Uganda) were paired with
compliance-speciﬁc virologic failure rates from the literature to
estimate the rates of treatment failure in each country. Any
patient with virologic failure was assumed to receive second-line
therapy. As a base case, we used published estimates of
HIV/AIDS annual per patient drug costs of $292 (in 2003
U.S.D.) in Uganda and $400 in South Africa for patients not
experiencing virological failure and $1594 (Uganda) and $1203
(South Africa) for patients that do experience virological failure.
The average annual per-patient drug cost was estimated for the
two countries from a non-governmental organization (NGO)
perspective. Sensitivity analyses were conducted on drug prices
and compliance rates. RESULTS: Given each country’s compli-
ance rates, the average virological failure rate was projected to
be 39% in Uganda and 68% in South Africa. The average drug
cost per patient was estimated to be $914 and $801 per year in
South Africa and Uganda, respectively. If compliance rates were
varied by +/- 25% of base case values, cost estimates ranged
from $841 to $987 for South Africa and from $756 and $935
for Uganda. Similarly, if drug costs were varied by +/- 25%, cost
estimates ranged from $685 to $1142 for South Africa and from
$601 to $1002 for Uganda. CONCLUSION: Patient compliance
is an important determinant of per-patient costs and overall
budgets for the drug cost of treating HIV/AIDS in Africa. Con-
sidering only ﬁrst and second-line unit costs does not accurately
reﬂect overall treatment costs.
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OBJECTIVES: To evaluate the psychometric properties of MINI-
HIV in HIV patients in Spanish population. METHODS: Valid-
ity, reliability and responsiveness of MINI-HIV were assessed
throughout observational, longitudinal and multicentric study
with 3 months of follow up. The 206 patients with HIV included
in the study were divided into two groups: 50 patients within the
reliability group (patients who were not foreseen any clinical
change in the following 15 days) and 156 patients within the
responsiveness group (patients that started a treatment or had a
treatment). Thus, 46 blood donor subjects were to include within
the control group. The main variable in the study was MINI-
HIV (17 items). Other variables analysed on the study were;
diagnosis date, disease symptoms, stage, previous HAART and
actual HAART, MOS-HIV and general health status. RESULTS:
The mean (SD) age of the participants was 37 (10.2), with a pre-
dominance of men (83.5 %). A total of 27.6% of the respon-
siveness group were “naïve” patients. 53.8% of the
responsiveness group and 68% reliability group patients took
only one HAART in the last year. 90% of patients answered all
questionnaire items. The mean time(SD) of questionnaire ﬁlling
by the patients was 12 (15.3) minutes. Regarding validity, MINI-
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HIV scoring showed a signiﬁcant relationship with scoring
assessed through MOS-HIV (R = -0.71; P < 0.01), and through
general health status (p < 0.01 ). MINI-HIV scoring showed a
signiﬁcant relationship with CD4 (p < 0.01), viral load and
symptoms (p < 0.001). Regarding responsiveness to change, a
high effect size in MINI-HIV was observed between those
patients whose general health status had improved during the
follow up visits (ES = 0.694 IC 95% 0.134–1.254). The internal
consistency of the questionnaire was assessed through the a
Cronbach (a = 0.93). The ICC (test—retest reliability) was 0.86.
CONCLUSIONS: The MINI-HIV has good psychometric prop-
erties and correlated with clinical markers of the disease.
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OBJECTIVES: This study aimed to assess the cross cultural
validity and reliability of Health Utility Index (HUI3) in UK HIV
population. METHODS: The study was approved by local
research ethics committee. All adult patients receiving HIV care
in Cardiff were approached in the outpatient clinic and recruited
into the study after giving written informed consent. Participants
were required to complete the HUI3. Variables analyzed include
QOL score, CD4+ category, HIV stage, antiretroviral (ARV)
usage and viral load using Spearman’s rank test, Kruskal-Wallis
and Mann-Whitney U test. RESULTS: In total, 103 (98%) of
participants completed the questionnaire. The average age of the
participant was 40.8 years (±10.7 SD) and 81 were male. HUI3’s
was found to be reliable in most attributes (Cronbach’s alpha
0.68), except in vision, hearing and ambulation. Four attributes
(ambulation, emotion, cognition and pain) correlated signiﬁ-
cantly with QOL score (p < 0.002) after controlling for anti-
retroviral use, clinical, and CD4+ categories. Findings also
revealed no signiﬁcant difference and correlation between QOL
score and CD4+ count, viral load count and HIV clinical cate-
gories. There appears to be a stronger correlation (r = -0.19) and
mean difference (P = 0.08) between QOL score and antiretrovi-
ral use but this did not reach statistical signiﬁcance. An inter-
esting pattern was observed whereby asymptomatic patients and
those not using antiretroviral (ARV) therapy had a lower QOL
score than AIDS patients. Class of ARV also appeared to affect
QOL score but was not signiﬁcant statistically (P = 0.2). CON-
CLUSION: The ﬁndings of this study support validity and reli-
ability of HUI3 in UK HIV population and therefore could be
used with conﬁdence in comparative study of HIV treatment.
The results also suggest beneﬁt of ARV use in improving patient
QOL and also the different effect of ARV regimen had on the
score; however this requires further investigation in a controlled
study.
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OBJECTIVES: A modeling study was conducted to assess the
balance between costs and effects of a hypothetical inﬂuenza vac-
cination programme in case of an inﬂuenza pandemic in The
Netherlands. METHODS: An existing decision model was
expanded to comprise the entire population at risk and pandemic
attack rate. Dutch estimates regarding costs, frequency of GP
visits, hospitalization and mortality associated with inﬂuenza
and inﬂuenza related complications were used. The impact in
terms of (dis-)utility of inﬂuenza and the various inﬂuenza
related complications were retrieved and added. A societal per-
spective was used to account for direct medical costs and costs
associated with sick leave. Monte-Carlo simulation was used to
conduct multivariable sensitivity analyses. RESULTS: In the
absence of vaccination the model predicted 517,567 GP visits,
41,766 hospitalizations and 72,513 deaths in case of a pandemic.
Vaccination of the population at risk would result in a reduction
of inﬂuenza infections (21%), GP visits (20%), hospitalizations
(34%) and deaths (30%). Net savings for society of €126 million
may be expected. Per person of the Dutch population the vacci-
nation program would lead to incremental costs of—€8.00 (99%
CI -€24.00 to €8.00). If only direct medical costs were taken into
account costs to society would be €68 million. Beneﬁts in terms
of QALY gain are positive but very small due to the short time
horizon of the analysis. The most important QALY losses are
observed in those individuals that die and those that experience
stroke or heart failure. Vaccination may prevent the death of
21,615 persons. The total number of life years gained is 16,627,
resulting in 12,790 QALYs gained. CONCLUSION: A vaccina-
tion programme in which high risk individuals are vaccinated in
accordance with the current inﬂuenza prevention program is cost
saving and generates extra (quality adjusted) life years.
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OBJECTIVES: To assess the cost-effectiveness of Palivizumab, a
prevention against respiratory syncytial virus (RSV) infections in
infants at high risk, such as premature babies, infants with bron-
chopulmonary dysplasia (BPD), and children with congenital
heart disease (CHD). METHODS: A decision tree model was
used to estimate the cost-effectiveness of Palivizumab in high-
risk children. The data sources included published literature, the
Palivizumab clinical trials, ofﬁcial price/tariff lists and national
population statistics. The primary perspective of the study was
that of the health care purchaser (National Health Service),
which included the cost of administration and hospital care for
RSV infections. RESULTS: The use of Palivizumab results in an
ICER of £7042/QALY without discounting, which increases to
£16,720/QALY after discounting in the prophylaxis in prema-
ture infants and such with BPD. In the prophylaxis in babies 
with CHD the use of Palivizumab results in an ICER of
£2427/QALY without discounting and £6664/QALY after dis-
counting. Sensitivity analyses conﬁrmed the robustness of the
model. A scenario analysis showed that the inclusion of indirect
costs leads to further improvement in the cost-effectiveness out-
comes for Palivizumab CONCLUSION: This study showed that
Palivizumab is a cost-effective prophylaxis against RSV-
infections in infants at high risk: the use of Palivizumab results
in positive short and long-term health economic beneﬁts to the
health care purchaser.
